Rize Oncology Announces Warrant Incentive Program

Kelowna, British Columbia — April 13, 2026 — Leads & Copy — Rize Oncology Inc., a clinical-stage pharmaceutical company, has announced a warrant incentive program to encourage the exercise of existing common share purchase warrants.

The Incentive Program applies to 25,000,000 common share purchase warrants initially issued on January 6, 2025, and 5,000,000 common share purchase warrants initially issued on October 30, 2025. Holders of warrants exercised on or before May 13, 2026, will receive a discounted exercise price of $0.02 per share and one common share purchase warrant for no additional consideration.

Each Incentive Warrant allows the holder to acquire one common share at $0.05 per share until December 31, 2028. The company expects to issue all Incentive Warrants around May 20, 2026. Holders can exercise all, some, or none of their outstanding warrants. Fractional Incentive Warrants will be rounded down to the nearest whole number.

The original exercise prices for the January and October Warrants were $0.05 and $0.30 per share, respectively. Warrants exercised under the Incentive Program by May 13, 2026, will have an exercise price of $0.02 per share. Unexercised warrants after 4:00 p.m. (Vancouver time) on May 13, 2026, will remain exercisable under their original terms.

To participate in the Incentive Program, warrant holders must deliver a completed exercise form, the original warrant certificate, an accredited investor certificate (or equivalent), and the discounted exercise price to the company by 4:00 p.m. (Vancouver time) on May 13, 2026.

The company intends to use the proceeds from the early exercise of warrants for general working capital. Common shares issued upon exercise of the outstanding warrants will not be subject to any hold period. However, the Incentive Warrants and any common shares issued upon their exercise will be subject to a four-month hold period after the distribution date of the Incentive Warrants.

Certain company insiders are expected to participate in the Incentive Program, potentially making it a "related party transaction" under Multilateral Instrument 61-101. The company plans to rely on exemptions from formal valuation and shareholder approval requirements based on the lack of specified market listing and financial hardship.

Rize Oncology Inc. focuses on developing STS-201, a small-molecule drug, for treating soft tissue sarcoma and other cancers.

Source: Rize Oncology Inc.